Highlight

1.Novel strategy for anti-PD-1/PD-L1 treatment resistance

1) Despite the great clinical success of immune checkpoint inhibitors, approximately 70% of patients still exhibit ineffective and adaptive resistance in PD-1/PD-L1 blockade anti-tumor therapy.

2) TIGIT is an inhibitory receptor, mainly expressed on NK cells and activated T cells and Treg cells. Dual blockade retains the pharmacodynamic activity of PD-1 inhibitors and inhibits the signal of TIGIT simultaneously, which synergistically enhances the efficacy. PD-1×TIGIT BsAb can be a strategy to overcome PD-1/PD-L1 blockade anti-tumor therapy resistance.

2.Asset binds to PD-1 and TIGIT simultaneously.

1）Asset is able to block both PD-1/PD-L1 pathway and TIGIT/CD155 pathway in vitro.

3.Excellent anti-tumor efficacy.

1) Asset shows enhanced SEB-induced-INF-γ secretion compared with Keytruda (anti-PD-1 mAb) and Tiragolumab (anti-TIGIT mAb) combination therapy, which remains more T cell activation.

2) Asset showed superior antitumor activity compared to the combination of Keytruda and Tiragolumab in vivo.

4.Good safety in preclinical study.

1) Cynomolgus monkeys were administered 3 weekly doses of 25 or 50 mg/kg of asset.

✓All animals were survived.

✓No toxicologically significant abnormalities were observed

✓NOAEL dose: 50 mg/kg

Research progress：

Preclinical stage;
Anti-tumor efficacy in preclinical study;
Good safety;